# A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of the Efficacy and Safety of Qifangfeixian Granules in the Treatment of Connective Tissue Disease-Associated Interstitial Lung Disease (CTD-ILD)

> **NCT06674148** · PHASE2,PHASE3 · RECRUITING · sponsor: **Huilan Zhang** · enrollment: 124 (estimated)

## Conditions studied

- Interstitial Lung Disease
- Qifangfeixian Granules

## Interventions

- **DRUG:** Qifangfeixian granules
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT06674148
- **Lead sponsor:** Huilan Zhang
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-10-25
- **Primary completion:** 2027-05-20
- **Final completion:** 2027-06-01
- **Target enrollment:** 124 (ESTIMATED)
- **Last updated:** 2024-11-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06674148

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06674148, "A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of the Efficacy and Safety of Qifangfeixian Granules in the Treatment of Connective Tissue Disease-Associated Interstitial Lung Disease (CTD-ILD)". Retrieved via AI Analytics 2026-06-22 from https://api.ai-analytics.org/clinical/NCT06674148. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*